Identifying aging and Alzheimer's disease associated somatic mutations in excitatory neurons from the human frontal cortex using whole genome sequencing and single cell RNA sequencing data

Meng Zhang^{1,2}, Gerard A. Bouland^{1,3}, Henne Holstege^{1,2}, Marcel J.T. Reinders^{1,3,*}

1 Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands
2 Department of Human Genetics, Amsterdam Neuroscience, Vrije Universiteit
Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

3 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

* Corresponding author E-mail: m.j.t.reinders@tudelft.nl (MJTR)

Abstract

With age, somatic mutations accumulated in human brain cells can lead to various neurological disorders and brain tumors. Since the incidence rate of Alzheimer's disease (AD) increases exponentially with age, investigating the association between AD and the accumulation of somatic mutation can help understand the etiology of AD. Here we built a somatic mutation detection pipeline by contrasting genotypes derived from WGS data with genotypes derived from scRNA-seq data and applied this pipeline to 76 participants from the ROSMAP project. We focused only on excitatory neurons, the dominant cell type in the human brain. As a result, we identified 196 sites that harbored at least one individual with an excitatory neuron-specific somatic mutation (ENSM) across all individuals, and these 196 sites were mapped to 127 genes. The single base substitution (SBS) pattern of the putative ENSMs was best explained by signature SBS5 from the COSMIC mutational signatures, a clock-like pattern correlating with the age of the individual. The count of ENSMs per individual also showed an increasing trend with age. Among the mutated sites, we found two sites to have significantly more mutations in older individuals (16:6899517 (*RBFOX1*), p =0.044; 4:21788463 (KCNIP4), p = 0.045). Also, two sites were found to have a higher odds ratio to detect a somatic mutation in AD samples (6:73374221 (KCNQ5), p = 0.014 and 13:36667102 (DCLK1), p = 0.023). 32 genes that harbor somatic mutations unique to AD and the KCNQ5 and DCLK1 genes were used for GO-term enrichment analysis. We found the AD-specific ENSMs enriched in the GO-term "vocalization behavior" and "intraspecies interaction between organisms". Interestingly, we observed both age- and AD-specific ENSMs enriched in the K⁺ channels-associated genes. Taken together this shows our pipeline that combines scRNA-seq and WGS data can successfully detect putative somatic mutations. Moreover, the application of our pipeline to the ROSMAP dataset has provided new insights into the association of AD and aging with brain somatic mutagenesis.

Author summary

Somatic mutations are changes in the DNA that occur during life. As with increasing age, somatic mutations also accumulate in human brain cells and can potentially lead to neurological diseases such as Alzheimer's disease (AD). Associating the occurrence of somatic mutations in human brains with increasing age as well as AD can provide new insights into the mechanisms of aging and the etiology of AD. But somatic mutations do not accumulate similarly across different cell types. Single cell RNA sequencing provides an opportunity to derive somatic mutations for different cell types. We describe a methodology to detect cell-type specific somatic mutations and demonstrate the effectiveness of this methodology by applying it to human brain single cell data of 76 participants from the ROSMAP project. The detected somatic mutational pattern resembles a known clock-like mutational signature, and the number of somatic mutations per person also increases with age. We also identify specific sites that have a higher incidence rate of somatic mutations in AD or associated with increasing age. We further use these findings to postulate molecular pathways enriched with somatic mutations in AD people contributing to the etiology of AD.

Introduction

Somatic mutations are post-zygotic genetic variations that can result in genetically different cells within a single organism. [1] Possible reasons for the occurrence and accumulation of somatic mutations in human brains are errors occurring during DNA replication and gradual failing of DNA repair mechanisms caused by extensive oxidative stress. [2,3] Previous studies have shown that brain somatic mutations originating in neuronal stem/progenitor cells can lead to various neurological disorders and brain tumors. [4–6] While mutations in post-mitotic neurons have been found to play an important role in age-related and neurodegenerative diseases, [7] this association remains relatively poorly understood. The link between the accumulation of age-related mutations in neurons and neurodegenerative disease is intuitively worth exploring, considering aging is a major risk factor for many neurodegenerative diseases, like Alzheimer's disease (AD) [8].

AD is the most predominant form of dementia, characterized by the extracellular accumulation of amyloid beta (A β) plaques and the intracellular aggregation of phosphorylated tau protein into neurofibrillary tangles (NFTs). [9, 10] A recent study identified several putative pathogenic brain somatic mutations enriched in genes that are involved in hyperphosphorylation of tau. [11] These results indicate that the aggregation of these neuropathological substrates can be partly explained by the accumulation of brain somatic mutations, which raises a new direction for investigating the pathogenic mechanism of AD.

Most age-related somatic mutations are only present in a small group of post-mitotic neurons or even in a single neuron. For this reason, ultra-deep bulk sequencing and matched peripheral tissues are often required. [11] This type of data is often generated for one specific research question with relatively high cost and are not always available from public databases. In contrast, the availability of public single cell RNA sequencing (scRNA-seq) datasets has exploded due to continuous technological innovations, increasing throughput, and decreasing costs. [12] scRNA-seq data is most often used for expression-based analyses, such as revealing complex and rare cell populations, uncovering regulatory relationships between genes, and tracking the trajectories of distinct cell lineages in development. [13, 14] We hypothesized that scRNA-seq data can also be used to detect somatic mutations.

In this study, we validated the feasibility of calling short somatic variants using

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

30

31

32

scRNA-seq data. We constructed a pipeline to detect brain-specific somatic mutation by contrasting genotypes identified with whole genome sequencing (WGS) data with genotypes identified with scRNA-seq data. For each putative somatic mutation we investigated associated genes and their respective association with AD and age. Additionally, we investigated whether AD and age are associated with an increasing number of somatic mutations.

Results

Excitatory neuron-specific somatic mutations (ENSMs)

To study somatic mutations acquired over age and between demented (AD) and non-demented (ND) persons, we collected 90 participants from the ROSMAP data for which WGS data in blood or brain as well as single nuclei RNA sequencing (snRNA-seq) data of the frontal cortex was present (Methods). Since the snRNA-seq data (n=90) were collected from three studies, the read coverage for samples varied between the studies (S1 Fig). To reduce the bias generated from the unbalanced read coverage, we excluded individuals (n=9) with a total read count smaller than 6×10^7 . Cells from the snRNA-seq data were annotated according to seven major cell types (Methods). As the amount of cells varied for different cell types (S2 Fig), we first explored the feasibility of detecting somatic mutations for each cell type. This exploratory analysis showed that somatic mutations were only detected from the excitatory neurons (when requiring a minimum number of reads (≥ 5) per sample for a putative variant site, Methods), the dominate cell type in snRNA-seq data. This underpins that a sufficient amount of cells was needed for snRNA-seq based somatic mutation detection. As a consequence, we focus our analysis on excitatory neurons. To further ensure the data quality, we excluded individuals (n=5) which had less than 200 excitatory neurons from our study. After filtering, 76 participants (23 from snRNAseqMFC study, 30 from snRNAseqPFC_BA10 study, and 23 from snRNAseqAD_TREM2 study) had an adequate read coverage and sufficient number of excitatory neurons. The demographic data (sex, age at death, and cognitive diagnosis (cogdx) categories [15]) of these participants are given in Table 1. More than 72% of them were 85 years of age or older at death; 56% were women. Individuals were grouped based on their cognitive diagnosis in either being non-demented (n=42) or being an AD sample (n=33).

ie in Summary characteristics of selected sample from the Rossinin study.				
Group	Cogdx*	n	\mathbf{Sex}	Age, mean \pm SD (range)
Non-demented	1	33	23 F; 19 M	$85.7 \pm 4.2 (76-90)$
	2	8		
	3	1		
Alzheimer's disease	4	32	19 F; 14 M	87.1 ±3.9 (74-90)
	5	1		
Other dementia	6	1	1 F	83

Table 1. Summary characteristics of selected sample from the ROSMAP study.

*Cognitive diagnosis (cogdx) is defined as six categories: 1 NCI: No cognitive impairment (No impaired domains); 2 MCI: Mild cognitive impairment (One impaired domain) and NO other cause of CI; 3 MCI: Mild cognitive impairment (One impaired domain) AND another cause of CI; 4 AD: Alzheimer's dementia and NO other cause of CI (NINCDS PROB AD); 5 AD: Alzheimer's dementia AND another cause of CI (NINCDS POSS AD); 6 Other dementia: Other primary cause of dementia.

34

35

36

37

38

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63



Fig 1. Schematic overview of the analyses in this study. a. Participants from the ROSMAP project with both single nuclei RNA sequencing (snRNA-seq) data and whole genome sequencing (WGS) data available were selected for this study. 76 participants who passed the total read number and cell number filtering were used for the analyses. These individuals (aged 74-90) were grouped as non-demented (ND) samples (n=42) or Alzheimer's disease (AD) patients (n=33) based on the cognitive diagnosis. b. The snRNA-seq data were collected from three studies (23 from snRNAseqMFC study, 30 from snRNAseqPFC_BA10 study, and 23 from snRNAseqAD_TREM2 study). All specimens for these three snRNA-seq data sources were collected post-mortem from the frontal cortex. The snRNA-seq data were clustered and assigned to seven major cell types, but only the reads from excitatory neurons were used for the study after an exploratory phase. The WGS data were measured from blood (n=23) or brain (n=53). c. The genotypes for snRNA-seq data were detected using the GATK pipeline followed by VarTrix, while the genotypes for WGS data were detected by the GATK pipeline (Method). d. The somatic mutations were determined by contrasting genotypes derived from WGS data with genotypes derived from snRNA-seq data. e. For the detected putative somatic mutations, their mutational signature, associated genes, and respective association with AD and age were investigated.

Number of detected ENSMs as expected

Somatic mutations in the 76 participants were detected using the pipeline described in the Methods and shown in Fig 1. For that the snRNA-seq data of the excitatory neurons are compared to WGS data of blood (n=23) or brain (n=53). IBD estimation using shared variation sites confirmed the matching between the snRNA-seq and WGS samples (pair-wised PI_HAT > 0.85, S3 Fig, Methods). From the 9,751,193 short variants called from the snRNA-seq data, we identified 196 sites that harbored at least one sample with an excitatory neuron-specific somatic mutation (ENSM) across all samples. These genetic sites map to 127 genes (Methods), and 104 sites among them were single-nucleotide variants (SNVs). From these 196 sites, 98 were shared between

70

71

72

73

74

multiple individuals (n > 2) (S4 Fig). A few sites have mutations present in almost all individual genomes, which are likely to be either RNA editing events [16]; transcription errors, which can occur in a wide variety of genetic contexts with several different patterns [17,18]; or technical errors [19]. 53 sites have mutations uniquely present in the brains of the AD samples (S1 Table).

Per individual genome the ENSMs ranged from 24 to 41. This seems to be in agreement with other studies that found an average of 12 somatic SNVs in hippocampal formation tissue using bulk exome sequencing [11], and an average amount of 1700 somatic mutations (substitutions 1500; indels 200) in neurons using a whole-genome duplex single-cell sequencing protocol [20].

Number of ENSMs increase with age

To characterize the ENSMs, a mutation signature analysis was performed on 104 putative somatic SNVs (Methods). The results show that, from the COSMIC mutational signatures, SBS5 best explains the observed pattern of putative somatic SNVs by Mutalisk (Fig 2). SBS5 is a clock-like signature, i.e. the number of mutations correlates with the age of the individual. This suggests that the underlying mutational processes of the found ENSMs might be part of the normal aging process in excitatory neurons. A previous study using bulk exome sequencing also found an abundance of the SBS5 signature in aged brain tissues. [11]



Fig 2. The mutation signature of 104 putative excitatory neuron-specific single nucleotide variations (SNVs) in the brain. Among the 30 COSMIC single base substitution (SBS) signatures, SBS5 was identified as the model that best explains the observed pattern of putative somatic SNVs by Mutalisk (BIC=892.6). a. The percentage of each substitution subtype in the 104 putative excitatory neuron-specific SNVs. Subtype T>C and C>T are the dominate subtypes, account for 43.3% and 35.6% of the fraction separately. b. The top panel shows the observed distribution of mutations across the 96 possible mutation types; the middle panel shows the difference of each base substitution subtype between the top and middle panel. c. The cosine similarity between the distributions of observed mutations and the best decomposition model (SBS 5).

75

76

77

78

79

80

81

82

83

84

86

87

89

90

91

92

When studying the count of somatic mutation in our analyses, we found only a slight increase with age ($\beta = 0.15$, Fig 3a) that was not statistically significant (p=0.12). We should note that the number of samples is relatively low and represent a relatively narrow age range (from 74 to 90 years old). Moreover, participants with an age older than 90 years were all censored by age 90, which could also influence the significance of the age trend. A significant trend is observed when we exclude individuals at age 90 from the regression ($\beta = 0.37$, P = 0.005; S5 Fig).



Fig 3. Quantitative comparison of the number of excitatory neuron-specific somatic mutations (ENSMs) in terms of AD and aging. a. The number of ENSMs per individual against the age of the individual. The line shows how this number regresses with age. The significance of the coefficient ($\beta \neq 0$) was tested using t-test. b. Boxplot of the number of ENSMs in non-demented controls (ND) and AD patients (AD). The Wilcoxon rank sum test does not show a significance difference (ns).

RBFOX1 and KCNIP4 harbor age-associating ENSMs

As several detected ENSMs are being detected in multiple individual genomes (S4 Fig), 102 we next tested the association of age with somatic mutation prevalence for each site 103 individually using a logistic regression (Methods). We added AD status as an 104 explanatory term and excluded the sample with other primary cause of dementia 105 (Methods) from this analysis. Two sites (16:6899517 (*RBFOX1*), p = 0.044; 4:21788463 106 (KCNIP4), p = 0.045) are found to have significantly more mutations in older 107 individuals. The age distributions in mutated and unmutated samples for these two 108 sites are shown in Fig 4. Some caution should be treated when interpreting this plot for 109 individuals older than 90 years as these are all mapped to 90 years old. 110

ENSM sites in *KCNQ5* and *DCLK1* associate with AD status

Genes that were enriched with somatic mutations in AD samples might have a higher possibility to be associated with AD. We found 53 ENSM sites that were only detected in AD samples. This prompted the question whether the number of ENSMs associate with AD status. A Wilcoxon rank sum test indicated that there was no significant difference (p=0.71) in the average count of ENSMs between AD samples and non-demented controls (Fig 3b). This finding is in line with a previous report [11,21]

94

95

96

98

99

100

101



Fig 4. The occurrence of somatic mutation with age in (a) *RBFOX1* and (b) *KCNIP4* genes. Logistic regression was used to test the prevalence of somatic mutations with increasing age.

that indicated that somatic mutations are associated with AD in certain patterns, but not by amount.

Next, we examined whether the occurrence of an ENSM is overrepresented within ¹²⁰ AD samples. A Fisher's exact test that identifies sites that have a higher odds ratio to ¹²¹ detect a somatic mutation in AD samples (Methods), yielded two sites with significant ¹²² odds ratios. These sites are mapped to two genes (6:73374221 (*KCNQ5*), p = 0.014 and ¹²³ 13:36667102 (*DCLK1*), p = 0.023). ¹²⁴

Genes harboring AD specific ENSMs do relate to Alzheimer or processes involved in Alzheimer

The 53 AD specific ENSM sites map to 42 genes. When we exclude genes for which also an ENSM occurs in an ND individual (n=10), we end up with 32 genes that have ENSMs only seen in AD samples (S1 File). Among these 32 genes, there are several well-known AD-associated genes, like SLC30A3, TTL, and CTSB, which thus harbor somatic mutations unique for AD.

Together with the two genes for which AD samples had a higher occurrence of ENSMs (*KCNQ5* and *DCLK1*), we conducted a GO-term analysis to investigate the biological pathways that may be involved (Methods). The most enriched biological processes is "vocalization behavior" (*FDR* < 0.009) which is known to be associated with AD. [22] Also, "intraspecies interaction between organisms" is found to be significant (*FDR* < 0.042), and detected genes with this function are *DLG4*, *CNTNAP2*, and *NRXN3* (Fig 5). Our results also identified a group of genes (*CACNA1B*, *CNTNAP2*, *DLG4*, *KCNQ3*, and *KCNQ5*) enriched with the GO-term "ion channel complex" (*FDR* < 0.031). *KCNQ* genes encode five members of the K_v7 family of K⁺ channel subunits (K_v7.1–7.5). Four of these (K_v7.2–7.5) are expressed in the nervous system. [23] Concerning AD-related neuropathology, a link between Aβ accumulation and K_v7 channels has been reported by some studies. [24, 25]

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142



Fig 5. GO-terms enriched with genes having AD-specific ENSMs. 32 genes that have ENSMs only seen in AD samples, and the *KCNQ5* and *DCLK1* genes that have a higher occurrence in AD samples are used in the GO-term enrichment analysis. The left panel of the figure shows the enriched terms, their corrected p-value, the number of genes annotated with that term (size of circle), and the fraction of overlapping genes that harbor a AD-specific ENSM (color of circle). The FDR corrected significant GO-terms are grouped into three categories: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF). The right panel shows the subset of genes having an AD-specific ENSM that are annotated with the enriched GO terms, red squares, while a blue squares indicates that the gene does not have that annotation. Those genes that are not annotated with any of these GO-terms are not included in this panel.

Discussion

Late-onset Alzheimer's disease, whose incidence increases with age, is often referred to as a geriatric disease. Although the accumulation of $A\beta$ peptide and phosphorylated tau protein are the neuropathological main characteristics of AD, they fail to explain the molecular pathogenesis. As such, a cell-level investigation might be necessary to study the underlying pathogenic mechanism. Here, we identified somatic mutations using public data collected from 76 ROSMAP donors and investigated their associations with AD and aging.

Although scRNA-seq data are normally used for expression-based analyses, our results have shown that scRNAseq data can be used for the detection of somatic mutations at a cell-type specific level. As long as RNA sequences align correctly to a reference genome, the pipeline that was used for variant calling can be used for both bulk RNA-seq and scRNAseq data. [26] However, calling variants for each cell separately is not efficient, suffers from low coverage, and each cell is likely to have a unique set of identified variants. For this reason, we aggregated cells per individual and per cell-type, generating cell-type specific pseudo-bulk data. An exploratory run of the pipeline revealed that this approach was only feasible for excitatory neuron as it was the most abundant cell type in the snRNA-seq data resulting in sufficient coverage. This observation shows that a sufficient amount of cells or relatively deep sequencing is required for somatic mutation detection.

144

152

153

154

155

156

157

158

159

160

161

162

Our analysis showed that the prevalence of somatic mutations in the gene KCNIP4and RBFOX1 is associated with increasing age (when corrected for AD status). KCNIP4 encodes a member of the family of voltage-gated potassium (K⁺) channel-interacting proteins (KCNIPs), which suggests altered ion transports/channels may be associated with the aging process. [27] RBFOX1 is a neuron-specific splicing factor predicted to regulate neuronal splicing networks clinically implicated in neurodevelopmental disorders. [28, 29] The increased somatic mutations in RBFOX1with age indicates neurodevelopmental disorders may also associate with human brain aging.

We detected the occurrence of somatic mutations close to well-known AD-associated genes, like *SLC30A3*, *TTL*, and *CTSB*. *SLC30A3* is known to be down-regulated in the prefrontal cortex of AD patients. [30] *SLC30A3* is assumed to play a protective role against ER stress, which has been thought to be involved to neurodegenerative diseases such as AD. [31] *TTL* is a cytosolic enzyme involved in the post-translational modification of alpha-tubulin. [32] A previous study found that levels of *TTL* were decreased in lysates from AD brains compared to age-matched controls and that, in contrast, D2 tubulin was significantly higher in the AD brains, indicating that loss of *TTL* and accompanying accumulation of D2 tubulin are hallmarks of both sporadic and familial AD. [33] Gene *CSTB* encodes cystatin B (CSTB), an endogenous inhibitor of cystine proteases. [34] Human CSTB has been proposed to be a partner of A β and colocalises with intracellular inclusions of A β in cultured cells. [35] Protein levels of CSTB have been also reported to increase in the brains of AD patients. [36] These observations suggest that somatic mutations may initiate or are involved in the AD process in many ways.

Advance AD-related dementia is often accompanied with language problems, behavioral issues and cognitive decline. [8] Our results identified AD associated somatic mutations in the genes CNTNAP2, DLG4, and NRXN3 which are involved in, among other processes, vocalization behavior, intraspecies interaction between organisms and behavior and cognition. Our results show that AD-related language problems and behavioral issues might be associated with somatic mutations in excitatory neurons. In addition, we identified AD-associated somatic mutations in CACNA1B, CNTNAP2, DLG4, KCNQ3 and KCNQ5, which are all ion-channels or involved with ion-channels. Previous studies have reported on the possible role of altered neuronal excitability, controlled by different ion channels and their associated proteins, occurring early during AD pathogenesis. [37, 38] Specifically K⁺ channels which are the most numerous and diverse channels present in the mammalian brain, may partly explain this alteration in neuronal excitability. [39] Also, a dysfunction of K^+ channels has been observed in fibroblasts [40] and platelets [36] of AD patients. Additionally, $A\beta$ has been demonstrated to not only be involve in the AD pathogenesis, but also modulate K⁺ channel activities [41] and may have a physiological role in controlling neuronal excitability [42]. Somatic mutations involved in K⁺ channels were detected to associate with both AD and age indicating the existence of common processes behind neurodegenerative disease and aging. It also seems that K^+ channels are naturally subjected to oxidation by reactive oxygen species (ROS) in both aging and neurodegenerative disease which are characterized by high levels of ROS. [43]

Calling variants and detecting somatic mutations from public scRNA-seq data²⁰⁹ expands the use scope of scRNA-seq data, and may provide new insight into postzygotic²¹⁰ genetic change at a cell-type specific level. The use of a single cell-type (excitatory²¹¹ neuron) and the minimal read coverage requirement minimized biases driven by²¹² gene-specific expression. However, some limitations can also not be ignored. With the²¹³ pipeline that was used, the results are sensitive to the chosen settings of the parameters.²¹⁴ RNA editing events and transcription errors that happen in RNA sequences might also²¹⁵

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

> be identified as somatic mutations using this pipeline, but the association between this 216 type of mutation and AD or aging could also be interesting. [44] Additionally, as the 217 pipeline is relatively complex, quality control was highly critical for this study. Another 218 limitation of this study is the relative narrow age range of the included individuals. 219 Moreover, ages above 90 were censored to be 90. These two factors may explain that we 220 only found a relative weak association between age and the accumulation of somatic 221 mutations. On the other hand, the significant trend after removing individuals with an 222 age higher than 90 might also indicate that nonagenarians and centenarians generally 223 have a more healthy individual genome. Next, heterozygous variants from the WGS 224 data were ignored in this study (due to potential ambiguity due to differences in gene 225 expression). Therefore, many potential somatic mutation were excluded from the start. 226 Finally, as 10x scRNA-seq data was used to detect somatic mutations, only variants 227 located on the DNA that gets transcribed into mRNA were detected. 228

Our study has explored the feasibility of using scRNA-seq data to detect somatic variants. We developed a pipeline that combines scRNA-seq and WGS data and successfully detected putative somatic mutations, as such, broadened the use-scope of scRNA-seq data. By applying this pipeline on data obtained from the ROSMAP project, we generated potential new insights into the association of AD and aging with brain somatic mutagenesis. It should be noted that follow-up studies with larger cohorts are required to validate our results.

Materials and methods

Case selection

Single nuclei RNA sequencing (snRNA-seq) data and whole genome sequencing (WGS) data were obtained from the Religious Order Study (ROS) and the Rush Memory and 239 Aging Project (MAP), two longitudinal cohort studies of aging and dementia. [45] 240 Information collected as part of these studies, collectively known as ROSMAP, includes 241 clinical data, detailed post-mortem pathological evaluations and tissue omics profiling. 242 The snRNA-seq data used in this project were from three sources: 1) snRNAseqMFC 243 study (n=24), 2) snRNAseqAD_TREM2 study (n=32) [46], and 3) snRNAseqPFC_BA10 244 study (n=48) [47]. All specimens for these three snRNA-seq data sources were collected 245 post-mortem from the frontal cortex, sub-regions might slightly differ between studies. 246 The snRNA-seq data from the three studies were all sequenced according to the 10x 247 Genomics manufacturer's protocol. The detailed information for cell partitioning, reverse transcription, library construction, and sequencing run configuration for the three studies is available on Synapse (snRNAseqMFC: syn16780177, snRNAseqAD_TREM2: syn21682120, snRNAseqPFC_BA10: syn21261143). WGS data was from a subset of the ROSMAP participants with DNA obtained from brain tissue, whole blood or lymphocytes transformed with the EBV virus. The details for WGS library preparation and sequencing, and WGS Germline variants calling were described in the previous study. [48] The individuals (n=90) that have both snRNA-seq data and 255 WGS data (27 from brain tissue and 63 from whole blood) available were selected for 256 this study. Individuals annotated with no cognitive impairment or mild cognitive 257 impairment were defined as non-demented (ND) controls; AD patients with or without 258 other cause of cognitive impairment were defined as AD samples. 259

Cell type annotation

Each snRNA-seq dataset was separately processed for clustering and cell type 261 annotation which was done as follows. The processed count matrix was loaded in Seurat

237 238

229

230

231

232

233

234

235

236

3.2.2. [49] The data was log-normalized and scaled before analysis. Next, with the 2,000 263 most variable genes (default with Seurat), principal components analysis (PCA) was 264 performed. The number of principal components used for clustering was determined 265 using the elbow method. Further, Seurat's FindNeighbours and FindCluster functions 266 were used, which utilizes Louvain clustering, the resolution was set at 0.5. A UMAP 267 plot (S6 Fig) was made to visualise and inspect the clusters. The following cell types 268 were identified using known and previously used markers: excitatory neurons (SLC17A7, 269 CAMK2A, NRGN), inhibitory neurons (GAD1, GAD2), astrocytes (AQP4, GFAP), 270 oligodendrocytes (MBP, MOBP, PLP1), oligodendrocyte progenitor cell (PDGFRA, 271 VCAN, CSPG4), microglia (CSF1R, CD74, C3) and endothelial cells (FLT1, 272 CLDN5). [47] Based on the markers' expression patterns across clusters determined by 273 Seurat's FindMarkers function, cell types were assigned to cells (S2 File). When clusters 274 were characterized by markers of multiple cell types, they were assigned "Unknown". 275

snRNA-seq short variants calling

Single nuclei RNA reads were mapped to the reference human genome GRCh37 using 277 STAR aligner (STAR v2.7.9a). After alignment, duplicate reads were identified using 278 MarkDuplicates (Picard v2.25.0) and reads with unannotated cell barcodes were 279 removed using samtools (smatools v1.11). Reads containing Ns in their cigar string were 280 splitted into multiple supplementary alignments using SplitNCigarReads (GATK 281 v4.2.0.0) to match the conventions of DNA aligner. Base Quality Recalibration was 282 performed per-sample to detect and correct for patterns of systematic errors in the base 283 quality scores using BaseRecalibrator and ApplyBQSR (GATK v4.2.0.0). Short variant 284 discovery was performed on chromosome 1-22 with a two-step process. HaplotypeCaller 285 was run on each sample separately in GVCF mode (GATK v4.2.0.0) producing an 286 intermediate file format called gVCF (for genomic VCF). gVCFs from each individual 287 were combined together and run through a joint genotyping step (GATK v4.2.0.0) to 288 produce a multi-sample VCF file. S7 Fig indicates the steps of snRNA-seq short variants 289 calling in a flow chart. Variant filtration was then performed using bcftools (bcftools 290 v1.11). A basic hard-filtering was performed using cutoffs of 1) the total read depth 291 DP < 50000; 2) the quality of calling QUAL>100; 3) the quality by depth QD > 2; 4) the 292 strand odds ratio SOR < 2; 5) the strand bias Fisher's exact test FS < 10. 203

Identical individual check using IBD estimation

To make sure the sequences of snRNA-seq and WGS are matching and from the same individual, we performed a pairwise identical by descent (IBD) estimation using filtered variants from snRNA-seq and WGS in a combined VCF file. The estimation was calculated using PLINK v1.9. [50] The proportion IBD value PLHAT from the output of PLINK was used as the estimator, when the profiles are from the same individual the PLHAT value will be close to 1, otherwise it will be close to 0.

Somatic mutation detection using VarTrix

VarTrix, a software tool for extracting single cell variant information from 10x Genomics single cell data, was used to detect somatic mutations. For single nuclei gene expression data, VarTrix requires a pre-called variant set in VCF format, an associated set of alignments in BAM or CRAM format, a genome FASTA file, and a cell barcodes file produced by Cell Ranger as input. After an exploratory phase, we observed that only cells annotated as excitatory neuron had enough read coverage for somatic mutation detection. Therefore, for each individual, a subset of the BAM file including only reads from cells annotated as excitatory neuron was used as the input of VarTrix.

276

294

Correspondingly, the pre-called variant set was also detected from the subset of the BAM file which only including barcodes from cells annotated as excitatory neuron.

Human reference genome GRCh37 was used as the genome FASTA file. In this 312 study, VarTrix was run in coverage mode generating a reference coverage matrix and an 313 alternate coverage matrix indicating the number of reads that support the reference 314 allele and the alternate allele. These matrices were later used for filtering variant sites 315 and detecting somatic mutations in the excitatory neurons. Since the snRNA-seq data 316 were collected from three studies, the average coverage varied between different sources. 317 To minimize the batch effect from different studies, we filtered the variant site based on 318 the read number of each individual. Specifically, we calculated a cutoff C_i for each 319 individual i as below: 320

$$C_i = \frac{n_i}{\sum_{i=1}^N n_i / N} C$$

where n_i is the number of reads for individual *i*, *N* is the number of individuals. 321 The constant value C is set as 25 to guarantee a relatively large minimum average read 322 coverage across individuals. A variant site would be used for somatic mutation detection 323 when for all individuals the read depth at this site is higher than the cut-off C_i for that 324 individual. Next, a somatic mutation was identified as present in one individual when: 325 1) the genotype of this individual at the site in WGS was ref/ref and the ratio of reads 326 that support the alternate allele is larger than 0.1 at the same site, or 2) the genotype 327 of this individual at the site in WGS was alt/alt and the ratio of reads that support the 328 reference allele is larger than 0.1 at the same site. When the genotype of a individual at 329 a certain site was heterozygote in WGS, we ignored the site for that individual, 330 regardless of the allele ratio in snRNA-seq, because we cannot distinguish an observed 331 homozygous variant at a site in snRNA-seq is due to somatic mutagenesis or reads 332 missing when there is a heterozygous variant in WGS at the same site. 333

Mutation signature analysis

To characterize the contribution of mutation signatures, we pooled all putative somatic single nucleotide variations (SNVs) for signature analysis. We formatted the pooled SNVs in a VCF file and used it as input for running Mutalisk [51] with the following configurations: maximum likelihood estimation (MLE) method; linear regression. The input file was compared with 30 single base substitution (SBS) signatures from the COSMIC mutational signatures database. The best model of signature combination was suggested from the tool by considering the Bayesian information criterion (BIC).

Variants annotation and effect prediction

The gene annotation and functional effect prediction for all putative variants were performed using SnpEff (SnpEff v5.0). [52] The human genome GRCh37 was used as reference genome. If there were multiple genes mapping to one variant site, the gene having higher putative effect was used for the disease and age association analyses.

GO-term enrichment analysis

The gene ontology (GO-term) enrichment analysis was performed using "topGo" package [53] in R and compressed by REVIGO [54] with semantic similarity score "Lin" [55]. The genes that were annotated to the variant sites with read depths higher than the cut-offs for all samples were used as background. The p-values from the uneliminated GO-terms were corrected using "Benjamini & Hochberg" method, significant results were reported with false discovery rate (FDR) < 0.05.

310

311

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

354 355 356

357

358

359

360

361

362

363

367

368

370

371

372

373

374

Statistical analysis

All calculations were performed using R (version 3.6.3). Wilcoxon rank sum test, linear regression, Fisher's exact test, and logistic regression were performed using the "stats" R package. [56] By categorizing the "present" of somatic mutation as 1 and the "absent" of somatic mutation as 0, the logistic function was defined as: $p = 1/(1 + exp(-(\beta_0 + \beta_1 age + \beta_2 group)))$, where age is the age of the sample at death, group is the assigned group for the individual based on the cogdx category, and $\beta_{0..2}$ are the coefficients of the intercept and the explanatory variables. For this analysis, only individuals from the AD and ND group were used.

Acknowledgments

We thank and acknowledge all participants and their family members of the ROSMAP study. We thank everyone in our life who has supported us both materially and spiritually.

Funding

This research was supported by an NWO Gravitation project: BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (NWO: 024.004.012).

Author Contributions

MZ, GAB, and MJTR conceived and designed the experiments. MZ and GAB performed the experiments and analyzed the data. MZ, GAB, HH, and MJTR wrote the manuscript. MJTR supervised the research. All authors read and approved the manuscript.

References

- 1. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nature Reviews Genetics. 2013;14(5):307–320. doi:10.1038/nrg3424.
- Maynard S, Fang EF, Scheibye-Knudsen M, Croteau DL, Bohr VA. DNA damage, DNA repair, aging, and neurodegeneration. Cold Spring Harbor Perspectives in Medicine. 2015;5(10). doi:10.1101/cshperspect.a025130.
- 3. Wang X, Wang W, Li L, Perry G, Lee Hg, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease; 2014.
- 4. Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. Science. 2013;341(6141). doi:10.1126/science.1237758.
- 5. Paquola ACM, Erwin JA, Gage FH. Insights into the role of somatic mosaicism in the brain; 2017.
- McConnell MJ, Moran JV, Abyzov A, Akbarian S, Bae T, Cortes-Ciriano I, et al. Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network. Science. 2017;356(6336). doi:10.1126/science.aal1641.

- Kennedy SR, Loeb LA, Herr AJ. Somatic mutations in aging, cancer and neurodegeneration. Mechanisms of Ageing and Development. 2012;133(4):118–126. doi:10.1016/j.mad.2011.10.009.
- Burns A, Iliffe S. Alzheimer's disease. BMJ (Online). 2009;338(7692):467–471. doi:10.1136/bmj.b158.
- Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications. 1984;120(3):885–890. doi:10.1016/S0006-291X(84)80190-4.
- Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. Journal of Biological Chemistry. 1986;261(13):6084–6089. doi:10.1016/S0021-9258(17)38495-8.
- Park JS, Lee J, Jung ES, Kim MH, Kim IB, Son H, et al. Brain somatic mutations observed in Alzheimer's disease associated with aging and dysregulation of tau phosphorylation. Nature Communications. 2019;10(1). doi:10.1038/s41467-019-11000-7.
- 12. Angerer P, Simon L, Tritschler S, Wolf FA, Fischer D, Theis FJ. Single cells make big data: New challenges and opportunities in transcriptomics; 2017.
- Hwang B, Lee JH, Bang D. Single-cell RNA sequencing technologies and bioinformatics pipelines. Experimental and Molecular Medicine. 2018;50(8):1–14. doi:10.1038/s12276-018-0071-8.
- Chen G, Ning B, Shi T. Single-cell RNA-seq technologies and related computational data analysis; 2019.
- Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–2204. doi:10.1212/01.WNL.0000271090.28148.24.
- Gott JM, Emeson RB. FUNCTIONS AND MECHANISMS OF RNA EDITING. https://doiorg/101146/annurevgenet341499. 2003;34:499–531. doi:10.1146/ANNUREV.GENET.34.1.499.
- Gout JF, Li W, Fritsch C, Li A, Haroon S, Singh L, et al. The landscape of transcription errors in eukaryotic cells. Science Advances. 2017;3(10). doi:10.1126/sciadv.1701484.
- Traverse CC, Ochman H. Conserved rates and patterns of transcription errors across bacterial growth states and lifestyles. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(12):3311–3316. doi:10.1073/pnas.1525329113.
- Navin NE. Cancer genomics: one cell at a time. Genome biology. 2014;15(8):452. doi:10.1186/s13059-014-0452-9.
- Abascal F, Harvey LMR, Mitchell E, Lawson ARJ, Lensing SV, Ellis P, et al. Somatic mutation landscapes at single-molecule resolution. Nature. 2021; p. 1–6. doi:10.1038/s41586-021-03477-4.

- 21. Keogh MJ, Wei W, Aryaman J, Walker L, van den Ameele J, Coxhead J, et al. High prevalence of focal and multi-focal somatic genetic variants in the human brain. Nature Communications. 2018;9(1):1–12. doi:10.1038/s41467-018-06331-w.
- 22. Yusupov A, Galvin JE. Vocalization in dementia: A case report and review of the literature. Case Reports in Neurology. 2014;6(1):126–133. doi:10.1159/000362159.
- 23. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels; 2009.
- 24. Mayordomo-Cava J, Yajeya J, Navarro-López JD, Jiménez-Díaz L. Amyloid- β (25-35) modulates the expression of GirK and KCNQ channel genes in the hippocampus. PLoS ONE. 2015;10(7):134385. doi:10.1371/journal.pone.0134385.
- 25. Durán-González J, Michi ED, Elorza B, Perez-Córdova MG, Pacheco-Otalora LF, Touhami A, et al. Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiology of Aging. 2013;34(8). doi:10.1016/j.neurobiolaging.2013.02.005.
- Liu F, Zhang Y, Zhang L, Li Z, Fang Q, Gao R, et al. Systematic comparative analysis of single-nucleotide variant detection methods from single-cell RNA sequencing data. Genome Biology. 2019;20(1):242. doi:10.1186/s13059-019-1863-4.
- 27. Kadish I, Thibault O, Blalock EM, Chen KC, Gant JC, Porter NM, et al. Hippocampal and cognitive aging across the lifespan: A bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment. Journal of Neuroscience. 2009;29(6):1805–1816. doi:10.1523/JNEUROSCI.4599-08.2009.
- Fogel BL, Wexler E, Wahnich A, Friedrich T, Vijayendran C, Gao F, et al. RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. Human Molecular Genetics. 2012;21(19):4171–4186. doi:10.1093/hmg/dds240.
- 29. Casanovas S, Schlichtholz L, Mühlbauer S, Dewi S, Schüle M, Strand D, et al. Rbfox1 Is Expressed in the Mouse Brain in the Form of Multiple Transcript Variants and Contains Functional E Boxes in Its Alternative Promoters. Frontiers in Molecular Neuroscience. 2020;13:66. doi:10.3389/fnmol.2020.00066.
- 30. Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobágyi T, Johnson M, et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: Association with cognitive impairment. Neurobiology of Aging. 2014;35(12):2836–2844. doi:10.1016/j.neurobiolaging.2014.06.015.
- Kurita H, Okuda R, Yokoo K, Inden M, Hozumi I. Protective roles of SLC30A3 against endoplasmic reticulum stress via ERK1/2 activation. Biochemical and Biophysical Research Communications. 2016;479(4):853–859. doi:10.1016/j.bbrc.2016.09.119.
- 32. Lewis SA, Cowan NJ. Tubulin Genes: Structure, Expression, and Regulation. In: Microtubule Proteins. CRC Press; 2018. p. 37–66.
- 33. Parato J, Kumar A, Pero ME, Qu X, Ramírez MB, Sproul A, et al. The pathogenic role of tubulin tyrosine ligase and D2 tubulin in Alzheimer's disease. Alzheimer's {\&} dementia : the journal of the Alzheimer's Association. 2021;17:e056351. doi:10.1002/alz.056351.

- 34. Turk V, Bode W. The cystatins: Protein inhibitors of cysteine proteinases; 1991.
- 35. Škerget K, Taler-Verčič A, Bavdek A, Hodnik V, Čeru S, Tušek-Žnidarič M, et al. Interaction between oligomers of stefin B and amyloid-{\$β\$} in vitro and in cells. Journal of Biological Chemistry. 2010;285(5):3201–3210. doi:10.1074/jbc.M109.024620.
- 36. De Silva HA, Aronson JK, Grahame-Smith DG, Jobst KA, Smith AD. Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. The Lancet. 1998;352(9140):1590–1593. doi:10.1016/S0140-6736(98)03200-0.
- 37. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease. Neuron. 2007;55(5):697–711. doi:10.1016/j.neuron.2007.07.025.
- 38. Frazzini V, Guarnieri S, Bomba M, Navarra R, Morabito C, Mariggiò MA, et al. Altered Kv2.1 functioning promotes increased excitability in hippocampal neurons of an Alzheimer's disease mouse model. Cell Death and Disease. 2016;7(2):e2100-e2100. doi:10.1038/cddis.2016.18.
- Zaydman MA, Silva JR, Cui J. Ion Channel Associated Diseases: Overview of Molecular Mechanisms. Chemical Reviews. 2012;112(12):6319–6333. doi:10.1021/CR300360K.
- Etcheberrigaray R, Ito E, Oka K, Tofel-Grehl B, Gibson GE, Alkon DL. Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proceedings of the National Academy of Sciences. 1993;90(17):8209–8213. doi:10.1073/PNAS.90.17.8209.
- 41. Plant LD, Webster NJ, Boyle JP, Ramsden M, Freir DB, Peers C, et al. Amyloid β peptide as a physiological modulator of neuronal 'A'-type K+ current. Neurobiology of Aging. 2006;27(11):1673–1683. doi:10.1016/j.neurobiolaging.2005.09.038.
- 42. Ramsden M, Henderson Z, Pearson HA. Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid β protein (1-40) is dependent on solubility status. Brain Research. 2002;956(2):254–261. doi:10.1016/S0006-8993(02)03547-3.
- 43. Sesti F. Oxidation of K+ channels in aging and neurodegeneration; 2016.
- 44. Anagnostou ME, Chung C, McGann E, Verheijen BM, Kou Y, Chen L, et al. Transcription errors in aging and disease. Translational Medicine of Aging. 2021;5:31–38. doi:10.1016/j.tma.2021.05.002.
- Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer's Disease. 2018;64(s1):S161–S189. doi:10.3233/JAD-179939.
- 46. Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature Medicine. 2020;26(1):131–142. doi:10.1038/s41591-019-0695-9.
- Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019;570(7761):332–337. doi:10.1038/s41586-019-1195-2.

- 48. De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Scientific Data. 2018;5. doi:10.1038/SDATA.2018.142.
- Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177(7):1888–1902. doi:10.1016/J.CELL.2019.05.031.
- Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising to the challenge of larger and richer datasets. GigaScience. 2015;4(1):7. doi:10.1186/S13742-015-0047-8/2707533.
- Lee J, Lee JK, Park J, Kwon Y, Park S, et al. Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for genomic, transcriptional and epigenomic signatures. Nucleic Acids Research. 2018;46(W1):W102–W108. doi:10.1093/NAR/GKY406.
- 52. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6(2):80–92. doi:10.4161/fly.19695.
- 53. Alexa A, Rahnenfuhrer J. topGO: Enrichment Analysis for Gene Ontology; 2019.
- Supek F, Bošnjak M, Škunca N, Šmuc T. Revigo summarizes and visualizes long lists of gene ontology terms. PLoS ONE. 2011;6(7):e21800. doi:10.1371/journal.pone.0021800.
- Lin D. An Information-Theoretic Definition of Similarity. In: In Proceedings of the 15th International Conference on Machine Learning. Morgan Kaufmann; 1998. p. 296–304.
- Core Development Team R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2020;2:https://www.R-project.org.

Supporting information

S1 Fig. The distribution of the number of single-nuclei RNA (snRNA) reads across individuals. The dashed red line indicates the cutoff of $< 6 \times 10^7$, individuals below this line were excluded from the study. The colors indicated the study that the individual was from. Individuals with color blue and red were from the two batches (B1 and B2) of snRNAseqMFC study; individuals with color orange were from snRNAseqAD_BA10 study; individuals with color purple were from snRNAseqPFC_TREM2 study.

S2 Fig. The number of cells per cell type per individual. The cell types were distinguished with seven different colors. Individuals with color blue and red were from the two batches (B1 and B2) of snRNAseqMFC study; individuals with color orange were from snRNAseqAD_TREM2 study; individuals with color purple were from snRNAseqPFC_BA10 study.

S3 Fig. IBD estimation between paired genetic profiles from WGS and snRNA-seq. The IBD estimation was performed to ensure the WGS and snRNA-seq profiles which share the same identifier were from the same individual. PI_HAT is a measure of overall IBD alleles. If the genetic profiles are from different persons, the value PI_HAT will be close to 0. On the contrary, if the profiles are from the same person, the value PI_HAT will be close to 1.

S4 Fig. Distribution of sample counts with excitatory neuron-specific somatic mutations at the same site.

S5 Fig. The count of mutations regressed with age. Individuals at age 90 were removed from this figure. The significance of the coefficient ($\beta \neq 0$) was tested using t-test.

S6 Fig. The UMAP plot for cell type clustering in each study. See Method for details.

S7 Fig. The pipeline of short snRNA-seq variants calling. This pipeline follows the best practices workflows from GATK.

S1 File. Supplementary file for AD specific ENSM sites.

S2 File. Supplementary file for cell type annotation.

S1 Table. Counting of mutagenic sites based on the cognitive diagnosis.